bdnf antisense oligonucleotide

**bdnf antisense oligonucleotide** is a synthetic oligonucleotide designed to **hybridize with the mRNA of brain-derived neurotrophic factor (BDNF)**, leading to downregulation or inhibition of BDNF gene expression. The antisense oligonucleotide binds sequence-specifically to BDNF mRNA, potentially interfering with processes such as splicing, transcription, or translation, and may induce degradation by RNase H if designed as a DNA-based oligonucleotide. The principal mechanism is the sequence-specific suppression of BDNF expression to investigate or therapeutically target pathways where BDNF is implicated, such as neurodegenerative diseases or memory consolidation. This approach is commonly used in animal models as a research tool and is discussed in patents as a therapeutic platform, but no individually named clinical product consisting of a bdnf antisense oligonucleotide has reached regulatory approval as of September 2025[1][3][7].

Other names

antisense oligonucleotide targeting BDNF